Amos Adler1, Omar Hussein2, Debby Ben-David2, Samira Masarwa2, Shiri Navon-Venezia3, Mitchell J Schwaber2, Yehuda Carmeli2. 1. National Center for Infection Control, Tel Aviv, Israel (affiliated with the Sackler School of Medicine, Tel Aviv University) amosa@tlvmc.gov.il. 2. National Center for Infection Control, Tel Aviv, Israel (affiliated with the Sackler School of Medicine, Tel Aviv University). 3. National Center for Infection Control, Tel Aviv, Israel (affiliated with the Sackler School of Medicine, Tel Aviv University) Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.
Abstract
OBJECTIVES: To study the molecular characteristics of carbapenemase-producing Enterobacteriaceae (CPE) in post-acute-care hospitals (PACHs) in Israel and to analyse the temporal changes between 2008 and 2013. METHODS: CPE isolates were obtained during two cross-sectional, point prevalence national surveys of PACHs in Israel performed in 2008 and 2013. Surveillance cultures were collected by streaking rectal swabs onto selective media. Isolates were identified to species level and tested for blaKPC, blaNDM and blaOXA-48 by PCR and by the Carba NP test. Molecular typing was done by PCR for the pilv-l gene, designed for the ST258 KPC-producing Klebsiella pneumoniae (KPC-KP) clone, BOX-PCR and MLST. RESULTS: The prevalence of CPE carriage in the first survey was 184/1147 (16%); all of the isolates were KPC-KP. The prevalence of CPE carriage in the second survey was 127/1287 (9.9%); of these isolates, 113 (89%) were KPC-KP, 9 (7%) were other KPC-producing species and 5 (4%) were NDM- and OXA-48-producing CPE (n = 1 and 4, respectively). The proportion of the KPC-KP population represented by the ST258 clone increased from 120/184 (65%) in 2008 to 91/113 (80%) in 2013. In 58% (71/122) of the KPC-CPE carriers identified in the 2013 survey, the source of acquisition was determined to be the PACH itself. All four OXA-48 CPE were acquired either directly or indirectly from patients arriving from the Palestinian Authority or Syria. CONCLUSIONS: Despite the decreased prevalence of CPE in Israeli PACHs, and the emergence of new types of CPE, the KPC-KP ST258 clone remains the predominant clone represented.
OBJECTIVES: To study the molecular characteristics of carbapenemase-producing Enterobacteriaceae (CPE) in post-acute-care hospitals (PACHs) in Israel and to analyse the temporal changes between 2008 and 2013. METHODS: CPE isolates were obtained during two cross-sectional, point prevalence national surveys of PACHs in Israel performed in 2008 and 2013. Surveillance cultures were collected by streaking rectal swabs onto selective media. Isolates were identified to species level and tested for blaKPC, blaNDM and blaOXA-48 by PCR and by the Carba NP test. Molecular typing was done by PCR for the pilv-l gene, designed for the ST258 KPC-producing Klebsiella pneumoniae (KPC-KP) clone, BOX-PCR and MLST. RESULTS: The prevalence of CPE carriage in the first survey was 184/1147 (16%); all of the isolates were KPC-KP. The prevalence of CPE carriage in the second survey was 127/1287 (9.9%); of these isolates, 113 (89%) were KPC-KP, 9 (7%) were other KPC-producing species and 5 (4%) were NDM- and OXA-48-producing CPE (n = 1 and 4, respectively). The proportion of the KPC-KP population represented by the ST258 clone increased from 120/184 (65%) in 2008 to 91/113 (80%) in 2013. In 58% (71/122) of the KPC-CPE carriers identified in the 2013 survey, the source of acquisition was determined to be the PACH itself. All four OXA-48 CPE were acquired either directly or indirectly from patients arriving from the Palestinian Authority or Syria. CONCLUSIONS: Despite the decreased prevalence of CPE in Israeli PACHs, and the emergence of new types of CPE, the KPC-KP ST258 clone remains the predominant clone represented.
Authors: David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Robert A Bonomo; Keith S Kaye Journal: Infect Control Hosp Epidemiol Date: 2015-05-20 Impact factor: 3.254
Authors: A Baraniak; R Izdebski; J Fiett; M Herda; L P G Derde; M J M Bonten; A Adler; Y Carmeli; H Goossens; W Hryniewicz; C Brun-Buisson; M Gniadkowski Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo Journal: Expert Opin Pharmacother Date: 2016-03-09 Impact factor: 3.889